{"id":"placebo-for-etanercept-subcutaneous-injection","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not interact with any molecular targets or receptors, and its primary purpose is to serve as a control in clinical trials for etanercept. This allows researchers to compare the efficacy and safety of etanercept to a treatment with no active ingredients.","oneSentence":"This drug is a placebo for etanercept subcutaneous injection, meaning it has no active therapeutic effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:06.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of moderate to severe rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT02308163","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-08-08","conditions":"Rheumatoid Arthritis","enrollment":509},{"nctId":"NCT02471144","phase":"PHASE3","title":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09-29","conditions":"Chronic Severe Plaque-type Psoriasis","enrollment":162},{"nctId":"NCT00585650","phase":"PHASE1, PHASE2","title":"Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2007-05","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT02373813","phase":"PHASE3","title":"Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-20","conditions":"Rheumatoid Arthritis","enrollment":371},{"nctId":"NCT02376790","phase":"PHASE3","title":"Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-03-03","conditions":"Psoriatic Arthritis","enrollment":851},{"nctId":"NCT01936688","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2013-09","conditions":"Plaque-type Psoriasis","enrollment":""},{"nctId":"NCT02346240","phase":"PHASE3","title":"Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2015-02-11","conditions":"Psoriasis, Plaque Psoriasis","enrollment":559},{"nctId":"NCT01646177","phase":"PHASE3","title":"A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07-28","conditions":"Psoriasis","enrollment":1346},{"nctId":"NCT01597245","phase":"PHASE3","title":"A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-05-18","conditions":"Psoriasis","enrollment":1224},{"nctId":"NCT00078806","phase":"PHASE3","title":"Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Amgen","startDate":"2001-06-04","conditions":"Juvenile Rheumatoid Arthritis","enrollment":19},{"nctId":"NCT03781375","phase":"PHASE3","title":"Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Amgen","startDate":"2000-08-24","conditions":"Juvenile Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT03780959","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)","status":"COMPLETED","sponsor":"Amgen","startDate":"1997-05-01","conditions":"Juvenile Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT01764997","phase":"PHASE3","title":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","status":"TERMINATED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":776},{"nctId":"NCT01313208","phase":"PHASE4","title":"Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":210},{"nctId":"NCT00789997","phase":"PHASE2, PHASE3","title":"TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2008-11","conditions":"COPD Exacerbation","enrollment":81},{"nctId":"NCT02701205","phase":"PHASE3","title":"Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis","status":"UNKNOWN","sponsor":"Shanghai Celgen Bio-Pharmaceutical Co.,Ltd","startDate":"2015-01","conditions":"Plaque Psoriasis, Psoriasis","enrollment":216},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01989689","phase":"PHASE2","title":"Etanercept and Vascular Function in Psoriasis","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-08","conditions":"PSORIASIS","enrollment":24},{"nctId":"NCT01298531","phase":"PHASE4","title":"A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Axial Spondyloarthritis","enrollment":90},{"nctId":"NCT00791765","phase":"PHASE4","title":"Moderate to Severe Plaque Psoriasis With Scalp Involvement","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-10","conditions":"Psoriasis","enrollment":124},{"nctId":"NCT01001208","phase":"PHASE3","title":"The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11","conditions":"Psoriasis","enrollment":478},{"nctId":"NCT00713544","phase":"PHASE2","title":"A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Rheumatoid Arthritis","enrollment":373}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for etanercept subcutaneous injection","genericName":"Placebo for etanercept subcutaneous injection","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a placebo for etanercept subcutaneous injection, meaning it has no active therapeutic effect. Used for Treatment of moderate to severe rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}